TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20437859

Group type: EXPERIMENTAL
Intervention: Short-course radiation plus adjuvant temozolomide (150-200 mg/m² for 5 days every 28-day cycle)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Short-course radiation (30 Gy in 6 fractions over 2 weeks)
Number of subjects: 45
Study: 17504798

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 16248466

Group type: EXPERIMENTAL
Intervention: Fast velocity isokinetic eccentric contractions (FST, 3.14 rad x s(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Slow velocity isokinetic eccentric contractions (SLW, 0.52 rad x s(‐1))
Number of subjects: 15
Study: 12664519

Group type: EXPERIMENTAL
Intervention: ALP (Alkaline Phosphatase)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LDH (Lactate Dehydrogenase)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multiple bone lesions (> 8)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Painful metastases (more than 7 in the VAS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Median survival
Number of subjects: 60
Study: 9513589

Group type: EXPERIMENTAL
Intervention: 23 valent pneumococcal vaccine
Number of subjects: 66
Study: 7608314

Group type: EXPERIMENTAL
Intervention: GITS (240 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GITS (120 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: PeHCl solution (given every 6 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Timed-release 12-hour pseudoephedrine capsule (given every 12 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GITS with high-fat breakfast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GITS without high-fat breakfast
Number of subjects: 24
Study: 2364843

Group type: EXPERIMENTAL
Intervention: Standard nicardipine (20 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sustained-release nicardipine (30 mg twice a day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both formulations of nicardipine
Number of subjects: 42
Study: 369991

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 4
Study: 31215037

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 64231
Study: 30920602

Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise intervention (supervised sessions thrice weekly for 16 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 27943372

Group type: EXPERIMENTAL
Intervention: Error Management Training (EMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Error Avoidance Training (EAT)
Number of subjects: 60
Study: 26881502

Group type: EXPERIMENTAL
Intervention: Supraclavicular radiation therapy (SC‐RT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (adjuvant chest wall/breast RT only)
Number of subjects: 40
Study: 23668671

Group type: EXPERIMENTAL
Intervention: BMI genetic risk score (GRS)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: WHR genetic risk score (GRS)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Diet low in fibre
Number of subjects: 459

Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 459
Study: 21044897

Group type: EXPERIMENTAL
Intervention: ICD therapy in low RVP (≤ 50%)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: ICD therapy in high RVP (> 50%)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: ICD therapy in low RVP (≤ 50%) during late phase
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: ICD therapy in high RVP (> 50%) during late phase
Number of subjects: 1057

Group type: COMPARATOR
Intervention: High RVP (> 50%) vs Low RVP (≤ 50%) in non-LBBB patients
Number of subjects: 1057
Study: 18675542

Group type: EXPERIMENTAL
Intervention: Low alcohol beer (3.8%)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Regular strength beer (5.3%)
Number of subjects: 34
Study: 17204591

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (simulated altitude of 4,000-5,500 m)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normoxia (500 m)
Number of subjects: 22
Study: 15548326

Group type: EXPERIMENTAL
Intervention: Hand-carried ultrasound (HCU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comprehensive echocardiography (CE)
Number of subjects: 44
Study: 11697839

Group type: EXPERIMENTAL
Intervention: irinotecan 175 mg/m2 given on days 1 and 10, repeated every three weeks for a total of six courses
Number of subjects: 38
Study: 9543310

Group type: EXPERIMENTAL
Intervention: Psychoeducational training
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study: 8156481

Group type: EXPERIMENTAL
Intervention: Western R1 resection with limited N1-level lymphadenectomy
Number of subjects: 389

Group type: COMPARATOR
Intervention: Japanese R2 resection with extended lymphadenectomy including N2-level
Number of subjects: 389
Study: 3408037

Group type: EXPERIMENTAL
Intervention: 5 mg nicergoline
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 ml saline
Number of subjects: 20
Study: 31710104

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg (with 240 mg loading dose)
Number of subjects: 1773

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1773
Study: 30615554

Group type: EXPERIMENTAL
Intervention: Radiomics fibrosis index (RFI)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Normalized liver enhancement
Number of subjects: 436

Group type: COMPARATOR
Intervention: Aspartate transaminase-to-platelet ratio index (APRI)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Fibrosis-4 index
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: RFI for diagnosing stage F2-F4
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: RFI for diagnosing stage F3-F4
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: RFI for diagnosing stage F4
Number of subjects: 436
Study: 28868630

Group type: EXPERIMENTAL
Intervention: Model-based conditional power assessment
Number of subjects: 0
Study: 26259632

Group type: EXPERIMENTAL
Intervention: Barley kernel-based bread (BB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference white wheat bread
Number of subjects: 20
Study: 23882169

Group type: EXPERIMENTAL
Intervention: Active implementation model for chronic disease management program for COPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual implementation model
Number of subjects: 0
Study: 21722959

Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine (K2: 10 mg and 25 mg doses at 11 and 4 hours preoperatively)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine (K3: 5 mg, 10 mg, and 25 mg doses at 17, 11, and 4 hours preoperatively)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (normal saline) for K2 (P2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (normal saline) for K3 (P3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1-ketamine-injection (K1: 25 mg at 4 hours preoperatively)
Number of subjects: 120
Study: 19155978

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) conversion
Number of subjects: 830

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI) continuation
Number of subjects: 830
Study: 16467647

Group type: EXPERIMENTAL
Intervention: Tailored dietary education to encourage a decrease in sodium intake and an increase in the intake of vitamin C and carotene, and of fruit and vegetables
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Tailored dietary education
Number of subjects: 550
Study: 14732749

Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing PCI
Number of subjects: 2694

Group type: COMPARATOR
Intervention: Nondiabetic patients undergoing PCI
Number of subjects: 2694
Study: 11407442

Group type: EXPERIMENTAL
Intervention: Targeted maintenance pharmacotherapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard-dose maintenance neuroleptic treatment
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups (Targeted and Standard-dose)
Number of subjects: 85
Study: 8986684

Group type: EXPERIMENTAL
Intervention: E1S (estrone sulfate) 0.625 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EqS (equilin sulfate) 0.3 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 17 alpha-ES (17 alpha-dihydroequilin sulfate) 0.2 mg
Number of subjects: 8
Study: 8275614

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naringin capsule
Number of subjects: 12
Study: 2886340

Group type: EXPERIMENTAL
Intervention: Beta-blockers (BB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beta-blockers + Chlorthalidone (BB + CTD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorthalidone (CTD)
Number of subjects: 60
Study: 28737273

Group type: EXPERIMENTAL
Intervention: CABG after ACS
Number of subjects: 3054

Group type: EXPERIMENTAL
Intervention: Younger, male subjects without metabolic syndrome and no history of chronic obstructive pulmonary disease, renal insufficiency, atrial fibrillation, or heart failure
Number of subjects: 3054
Study: 26922669

Group type: EXPERIMENTAL
Intervention: Synthetic cartilage implant
Number of subjects: 202

Group type: COMPARATOR
Intervention: Arthrodesis
Number of subjects: 202
Study: 25363178

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Indomethacin 100 mg PRN and hydration (control group)
Number of subjects: 96
Study: 22538682

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional bipolar instruments
Number of subjects: 100
Study: 20102995

Group type: EXPERIMENTAL
Intervention: Brief counseling intervention delivered by a primary care physician
Number of subjects: 752
Study: 18565217

Group type: EXPERIMENTAL
Intervention: Systemic methotrexate (MTX) - single dose intramuscular regimen (1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study: 16087057

Group type: EXPERIMENTAL
Intervention: ACTH treatment (n = 26)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oral steroid treatment (n = 18)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No treatment (n = 25)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-dose ACTH
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ACTH treatment
Number of subjects: 69
Study: 11821278

Group type: EXPERIMENTAL
Intervention: Withdrawal of vaginal progesterone from the day of positive HCG (study group, n = 150)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Continued administration of vaginal progesterone for 3 weeks after positive HCG (control group, n = 153)
Number of subjects: 303
Study: 10953944

Group type: EXPERIMENTAL
Intervention: Participation in the early intervention program (Infant Health and Development Program)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Service patterns at age 5
Number of subjects: 869
Study: 9175992

Group type: EXPERIMENTAL
Intervention: Diet A (12% protein)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diet B (21% protein)
Number of subjects: 55
Study: 1551495

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3929067

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy consisting of Tegafur, Adriamycin (ADM), Mitomycin C (MMC) and OK432
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Tegafur and ADM
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Tegafur alone
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Tegafur and MMC
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: MMC during operation
Number of subjects: 189
Study: 29450689

Group type: EXPERIMENTAL
Intervention: Home telemonitoring group (n=90)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care group (n=91)
Number of subjects: 181
Study: 26699690

Group type: EXPERIMENTAL
Intervention: General anaesthesia combined with thoracic epidural anaesthesia (TEA)
Number of subjects: 219

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: General anaesthesia combined with infusion of 1 μg/kg dexmedetomidine
Number of subjects: 219
Study: 24838844

Group type: EXPERIMENTAL
Intervention: Pathways to Freedom (PTF) DVD
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard control DVD
Number of subjects: 140
Study: 22805901

Group type: EXPERIMENTAL
Intervention: Information Technology‐Aided Program of Relapse Prevention in Schizophrenia (ITAREPS)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: ITAREPS Algorithm-Adherers (IAAs)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 146
Study: 20087363

Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator (tPA)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 18765877

Group type: EXPERIMENTAL
Intervention: 12 ml/kg Ringer lactate iv (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 12 ml/kg 4.5% hydroxyethylstarch (Hetastarch) iv (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 ml/kg Ringer lactate iv (Group A)
Number of subjects: 60
Study: 15885641

Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoid (prednisolone) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12665325

Group type: EXPERIMENTAL
Intervention: Immediate androgen deprivation (IAD) prior to conformal radiotherapy for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Deferred treatment strategy (DAD)
Number of subjects: 25
Study: 10378632

Group type: EXPERIMENTAL
Intervention: Ifosfamide (5.0 g/m2) and epirubicin (80 mg/m2) with r‐metHuG‐CSF 5 microg/kg subcutaneously daily for 10 days (cohort A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ifosfamide (5.0 g/m2) and epirubicin (80 mg/m2) with r‐metHuG‐CSF 5 microg/kg subcutaneously daily for 7 days (cohort B)
Number of subjects: 17
Study: 9081356

Group type: EXPERIMENTAL
Intervention: High uPA tumours (uPA > 0.62 ng/mg protein)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Not treated with systemic adjuvant therapy
Number of subjects: 688
Study: 30230026

Group type: EXPERIMENTAL
Intervention: Nurse, dietician and physiotherapist group (n=27)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nurse and dietician group (n=29)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combined treatment groups (n=56)
Number of subjects: 64
Study: 30036082

Group type: EXPERIMENTAL
Intervention: Reduced SMBG frequency >1 test/day
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Reduced SMBG frequency ≤1 test/day
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Highest quartile of SMBG frequency reduction (≥2.2 fewer tests/day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Lowest quartile of SMBG frequency reduction (≤0.4 fewer tests/day)
Number of subjects: 175
Study: 27342507

Group type: EXPERIMENTAL
Intervention: Conventional dose of bortezomib
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reduction dose of bortezomib
Number of subjects: 150
Study: 24566903

Group type: EXPERIMENTAL
Intervention: 20% diluted autologous serum (AS) eye drops
Number of subjects: 20

Group type: COMPARATOR
Intervention: Preservative-free artificial tears (PFAT)
Number of subjects: 20
Study: 22248153

Group type: EXPERIMENTAL
Intervention: Avanafil (50 mg, 100 mg, 200 mg)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 646
Study: 17891409

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 1 g (Perfalgan)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 76
Study: 15893524

Group type: EXPERIMENTAL
Intervention: Duple and triple classes of rhythm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metrical melodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-metrical melodies
Number of subjects: 0
Study: 14565658

Group type: EXPERIMENTAL
Intervention: Pamidronate (PMD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study: 10800818

Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8764800

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide twice daily
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: 0.7% dorzolamide twice daily
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: 2% pilocarpine four times daily
Number of subjects: 293

Group type: COMPARATOR
Intervention: 2% pilocarpine
Number of subjects: 293
Study: 1484739

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IC)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ceftazidime-vancomycin (CV)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ticarcillin-amikacin-vancomycin (TVA)
Number of subjects: 183
Study: 3860335

Group type: EXPERIMENTAL
Intervention: Dental health education through home visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dental health education through leaflets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no dental health education)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride supplements (for children of mothers who received personal advice)
Number of subjects: 0
Study: 29782407

Group type: EXPERIMENTAL
Intervention: Heel group (gait training by active weight bearing on the paretic heel with auditory feedback)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Forefoot group (gait training with auditory feedback from paretic metatarsals)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (general gait intervention)
Number of subjects: 31
Study: 26640036

Group type: EXPERIMENTAL
Intervention: S-1 plus leucovorin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: S-1 plus leucovorin and oxaliplatin
Number of subjects: 145

Group type: COMPARATOR
Intervention: S-1 plus cisplatin
Number of subjects: 145
Study: 24822154

Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional septoplasty
Number of subjects: 50
Study: 22473769

Group type: EXPERIMENTAL
Intervention: bapineuzumab
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 20739218

Group type: EXPERIMENTAL
Intervention: Bortezomib plus thalidomide and prednisone (VTP)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Bortezomib plus melphalan and prednisone (VMP)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Bortezomib plus thalidomide (maintenance)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Bortezomib plus prednisone (maintenance)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: VTP
Number of subjects: 260

Group type: COMPARATOR
Intervention: VMP
Number of subjects: 260
Study: 17565633

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mesalazine + cholestyramine
Number of subjects: 64
Study: 15945446

Group type: EXPERIMENTAL
Intervention: Short-term controlled treatment (DOTS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Individual treatment regimens
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Quadruple-combination therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: At least 5 antituberculous drugs
Number of subjects: 66
Study: 12527599

Group type: EXPERIMENTAL
Intervention: AeroDose 90 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: AeroDose 30 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: AeroDose 60 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: PARI LC PLUS 300 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: AeroDose (all doses)
Number of subjects: 53
Study: 10473238

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g single dose)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vancomycin (500 mg i.v. every 6 h for 48 h)
Number of subjects: 200
Study: 8888369

Group type: EXPERIMENTAL
Intervention: AMPT 1 g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Promethazine 50 mg (placebo)
Number of subjects: 10
Study: 1676083

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (1 kg milk-based formula per week for 2 years)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (weekly play sessions at home with a community health aide)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Combined interventions (supplemented plus stimulated)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 129
Study: 6603287

Group type: EXPERIMENTAL
Intervention: Digoxin (1 mg iv over 24 hr, then 0.25 mg/day) and Propranolol (10 mg every 6 hr)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 179
Study: 30725040

Group type: EXPERIMENTAL
Intervention: Case management approach
Number of subjects: 644

Group type: COMPARATOR
Intervention: Usual care model (control)
Number of subjects: 644
Study: 26891420

Group type: EXPERIMENTAL
Intervention: Tivantinib (360 mg/m² twice daily) plus biweekly cetuximab (500 mg/m²) and irinotecan (180 mg/m²)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo plus biweekly cetuximab (500 mg/m²) and irinotecan (180 mg/m²)
Number of subjects: 117
Study: 24926781

Group type: COMPARATOR
Intervention: Baseline profile patterns of demographic, immunologic, and metabolic markers
Number of subjects: 356
Study: 22182361

Group type: EXPERIMENTAL
Intervention: Oral Health Promotion (OHP) program implemented in nine schools since 2005
Number of subjects: 478

Group type: COMPARATOR
Intervention: Schools without the OHP program
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: OHP program in four schools
Number of subjects: 478
Study: 20533444

Group type: EXPERIMENTAL
Intervention: ePTFE-covered stent
Number of subjects: 60

Group type: COMPARATOR
Intervention: bare stent
Number of subjects: 60
Study: 18794027

Group type: EXPERIMENTAL
Intervention: Aspirin 320 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aspirin 0 mg
Number of subjects: 16